Onconetix, Inc.

Onconetix, Inc. provided an update on Realbotix LLC, its pending acquisition target. Realbotix announced a partnership with Bloom Procurement Services to launch a pilot program deploying socially assistive humanoid robots in UK care settings to combat loneliness and improve wellbeing among older adults. Realbotix has also been accredited as a supplier on Bloom’s public sector marketplace. The acquisition of Realbotix LLC by Onconetix is an all-stock transaction, anticipated to close in the second half of 2026, subject to shareholder and regulatory approvals.

Onconetix, Inc. provided an update regarding its pending acquisition target, Realbotix LLC. Realbotix has launched a pilot program at Salamanca City Central School District, deploying its AI-powered teacher's assistant, Optio, and an M-Series humanoid robot. The program is set to expand to approximately 500 high school students by Fall 2026. Onconetix previously announced its definitive agreement to acquire Realbotix LLC in an all-stock transaction, with closing anticipated in the second half of 2026, subject to shareholder and regulatory approvals.

Onconetix, Inc. announced a 1-for-10 reverse stock split of its common stock, effective 12:01 a.m. Eastern Time on May 21, 2026. The Board of Directors fixed the ratio on May 8, 2026, following stockholder approval on April 30, 2026. This action is primarily intended to bring the company into compliance with Nasdaq's minimum bid price requirement. Trading on a split-adjusted basis will commence on May 21, 2026, under a new CUSIP number.

Onconetix, Inc. announced that its Board of Directors has approved a 1-for-10 reverse stock split of its common stock, effective May 21, 2026. This action, previously approved by stockholders, is intended to help the company maintain compliance with The Nasdaq Capital Market's minimum bid price requirement. Following the split, the number of outstanding shares will be reduced from approximately 11.4 million to 1.14 million, with fractional shares being compensated in cash.

Onconetix, Inc. announced Q1 2026 operational and clinical progress for its Swiss subsidiary, Proteomedix AG, developer of the Proclarix® diagnostic blood test. The update highlighted two new peer-reviewed publications reinforcing Proclarix's performance and prognostic value. Additionally, Proteomedix initiated the multi-center PRIME study with Labcorp Holdings Inc. in the U.S. to evaluate Proclarix, alongside continued European commercial expansion.

Onconetix's subsidiary, Proteomedix AG, provided Q1 2026 operational updates for its Proclarix® diagnostic blood test. New peer-reviewed clinical data reinforced Proclarix®'s ability to reduce overdiagnosis and unnecessary biopsies for prostate cancer. The company initiated the multi-center PRIME study in collaboration with Labcorp to evaluate Proclarix® for the U.S. market, with up to 500 men to be enrolled. Additionally, European commercial expansion advanced, with nearly 100 tests performed in a UK screening initiative and a new partnership identified in Turkey.

Onconetix reported a net loss of $4.21 million for Q1 2026, an improvement from $8.55 million in Q1 2025, largely due to changes in fair value of derivative liabilities. However, revenue significantly decreased to $21,457 from $101,630 in the prior year. The company continues to incur substantial operating losses and has a cash balance of $3.7 million as of March 31, 2026, raising substantial doubt about its ability to continue as a going concern. Management plans to pursue additional equity or debt financing to support operations and strategic initiatives.

Onconetix, Inc. filed an S-1 registration statement, including an exhibit list detailing recent corporate activities. Key among these is a Share Exchange Agreement dated February 11, 2026, involving Onconetix, Realbotix, LLC, Realbotix Corp, and Simulacra Corporation. The filing also highlights recent capital raising efforts through the sale of Series D and E Preferred Stock and Warrants, various promissory notes, and amendments to corporate governance documents.

Onconetix, Inc. announced that its stockholders approved a reverse stock split proposal at a special meeting held on April 30, 2026. The approved amendment allows for a reverse stock split of the company's common stock at a ratio between 1-for-2 and 1-for-10, to be determined by the Board of Directors. Stockholders also approved a proposal to adjourn the meeting if necessary to solicit additional proxies.

Onconetix, Inc. (ONCO) filed an S-1 registering up to 25,000,000 shares for resale by Keystone Partners, LLC under an equity line of credit (ELOC), through which ONCO may receive up to $25.0 million. The company also announced a proposed Share Exchange Agreement to acquire Realbotix Corp., which would result in Realbotix's seller owning 75-90% of ONCO's fully diluted shares, subject to conditions including ONCO having at least $12.5 million Net Cash. These developments follow a one-for-five reverse stock split in March 2026 and recent management changes, as the company continues to face substantial doubt about its ability to continue as a going concern.